Overview

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Status:
WITHDRAWN

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter study to evaluate the safety, tolerability, and efficacy of HMPL-523 in adult subjects with ITP.

Phase:

PHASE1

Details

Lead Sponsor:

Hutchmed